Hepatitis Studies

Shyam Kottilil M.D., Ph.D.Laboratory of Immunoregulation

National Institute of Allergy and InfectiousDiseases

National Institutes of HealthDepartment of Health and Human Services

Bethesda, MD

Hepatitis C and HIV coexist in the US

0

1

2

3

4

5

Num

ber a

ffect

ed (m

illio

ns)

HCV

HIV

Sulkowski MS, Mast EE, Seeff, LB et al. Hepatitis C Virus Infection as an Opportunistic Disease in Persons infected with Human Immunodeficiency Virus. Clin Infect Dis. 2000;30:577-84.

Population

All HIV+

0

20

40

60

80

100

Perc

enta

ge

IVDU90%

33%

Population

Washington, D.C. Our Nation’s Capital

3%=18000 HIV+

1.8%=12000 HCV+

Establishment of Hepatitis Clinics

Average Incidence Rateper 100,000 Population

0 - 25.025.1 – 50.050.1 – 75.075.1 – 100.0100.1 – 125.0

Numbers found below each ward refer to the rate of newly reportedHIV cases per 100,000 population. Rates were calculated using 2000 Census data.

For 16% of cases, ward information was not available and therefore not displayed on this map.

HCV/HIVHCVHIV/HBVHBVHIV/HCV/HBV

Hepatitis Treatment Protocols-DC-PFAP

GS-7977+RBV Anti-fibrosis

Jan Mar Sept Dec Mar JuneJune Sept

HCV DAA Tx

Peg+RBV+PI (Boc) IFN and RBV FREE Tx

TLR7 PHASE 1

Anti-fibrosis

HCV-DAA

HCV-DAA

TLR7 Phase 1Natural History

Anti-fibrosis

Most Effective HIV Program

Most Effective Hepatitis Program

Washington, D.C. Our Nation’s Capital